OncoGenex Pharmaceuticals Awarded BIOTECanada's Biotech Company of the Year Award

12-Apr-2010 - Canada

OncoGenex Pharmaceuticals, Inc. announced that the Company will be presented with BIOTECanada's gold Leaf Award as biotech company of the year. The award recognizes a biotech company that has distinguished itself from its peers with strong overall performance as a company, demonstrated leadership and shown significant achievement.

In 2009 OncoGenex announced Phase 2 data from its OGX-011 drug development program, showing a median survival advantage of 6.9 months compared to patients treated only with the current standard of care. The company also confirmed its Phase 3 development plans with the FDA via the Special Protocol Assessment process. In December of 2009, OncoGenex secured a major global partnership with Teva Pharmaceutical Industries to develop and commercialize OGX-011. Following a successful equity financing as well as cash secured through the Teva partnership, OncoGenex closed 2009 with $64.6 million in cash, its strongest cash position in company history.

"2009 was a tremendous year for OncoGenex, and we are honored to be recognized with this esteemed award," said Scott Cormack, president and chief executive officer of OncoGenex. "We are currently focused on a number of accomplishments ahead of us, including initiating Phase 3 clinical trials of OGX-011 in prostate and lung cancer and the advancement of our pipeline programs including OGX-427."

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

CMC Biologics Announce Appointment of David Wolton as VP Manufacturing

Revotar announces promising results suggesting COPD as a potential target for selectin antagonist treatment in humans

GPC Biotech AG Named in Purported Class Action Lawsuit in the United States

Dr. Andrew Zhu Joins Chemokine Therapeutics' Clinical Advisory Board

Currently positioned only 5th, China is the fastest growing biotech market in the world

BGU researchers make scientific breakthrough in the fight against neurodegenerative diseases - BGN Technologies secures funding of over $1m. to develop patented treatment

Pivotal phase IIIa trials for Organon's novel oral contraceptive, NOMAC/E2, complete recruitment

Gene Logic Expands GeneExpress Product Line, Launches GeneExpress Women's Health DataSuite - New Product Enables Analysis of Distinctions in Female and Male/ Female Gene Expression

Cangene's VIG (Vaccinia Immune Globulin Intravenous) contract with U.S. government extended for another five years

MediGene successfully completes patient recruitment into EndoTAG(TM)-1 Phase II breast cancer trial

Immatics Enters Collaboration with Cancer Research UK to Develop Multi-target Rationally Designed Therapeutic Cancer Vaccine - IMA950 to enter Phase I development for glioblastoma, the most aggressive form of brain cancer

New findings about stem cells in the brain of patients with epilepsy